Leqvio Side-Effect Reports: Compare Stories With the Evidence

A story about symptoms after Leqvio (inclisiran) can help you formulate a question for your treating team. It cannot establish how often that symptom occurs or whether the injection caused it. The useful comparison is between the story’s specific details and evidence collected in a defined study population.

There is no verified, systematically collected online-review corpus behind this page. We therefore cannot rank forum complaints or calculate their frequency. Timing, severity, recurrence and effects on daily activity are more useful than an unsupported claim that a symptom is “common online.”

What the adult controlled evidence shows

The current prescribing information pools three placebo-controlled adult trials: 1,833 participants received inclisiran and 1,822 received placebo. [1]

Rates are rounded. The injection-site category includes pain, redness and rash. The table lists reactions occurring in at least 3% of treated adults and more often than with placebo; it is not an inventory of every possible symptom. A six-percentage-point difference is not a sixfold relative risk. [1]

ORION-10 and ORION-11 were randomized, double-blind trials lasting 540 days, with 3,178 participants combined. Injection-site events occurred in 2.6% versus 0.9% in ORION-10 and 4.7% versus 0.5% in ORION-11. They were generally mild, with none reported as severe or persistent. [2]

Those individual-trial figures and the current three-trial label pool have different scopes. Keep each rate attached to its study rather than averaging them or treating the differences as a contradiction. An observed group rate also cannot predict an individual’s experience.

What longer follow-up adds

Long-term data exist, with important design limits. ORION-3 was a four-year, open-label extension of ORION-1. Injection-site events were reported in about 14% of each safety group across that period. Participants knew their treatment, and there was no contemporaneous long-term placebo comparison. Its selected completers came from the parent trial, rather than forming an independent new population. [3]

ORION-8 followed participants from preceding phase 2 and 3 studies in another open-label extension. Mean cumulative exposure, including parent studies, was 3.7 years; the maximum was 6.8 years. Of 3,274 participants, 74.7% continued until study end. Injection-site events were reported in 5.9% and were mild or moderate; no new safety signals were identified. [4]

This extends observation beyond the controlled trials. However, “no new signals” does not mean every rare harm has been excluded. Without placebo in the extension, its rate cannot be compared directly with the controlled-trial percentages.

Read the symptom story separately from the service review

A negative review may describe pain, difficulty arranging an appointment, or a billing dispute. Those are different outcomes. Access problems matter, but they do not measure physical tolerability. People with difficult experiences may be more motivated to post; that is a plausible selection problem, not a measured finding about Leqvio reviews here.

For fatigue or muscle pain, look for a precise description rather than a presumed explanation. A symptom starting after an injection deserves attention, but sequence alone does not establish causation. These sources do not establish a usual duration for such symptoms or prove a nocebo explanation. [1–4]

Build a record your treating team can use

Write down the injection date, when each symptom began, its body location and severity, and what activities it affected. Add whether it improved, persisted or returned, plus recent illnesses and medication changes. A dated photograph may help document a visible reaction. Keep appointment or billing problems in a separate note. Your team can use that record to evaluate the pattern you experienced.

Frequently asked questions

›What are the most common Leqvio side effects that patients report online?

No verified online-review dataset here establishes that ranking. The adult trial table above provides measured rates for injection-site reactions, joint pain and bronchitis. [1]

›How long do Leqvio side effects usually last, based on patient reports?

Individual online stories cannot establish the usual duration. ORION-10 and ORION-11 reported generally mild injection-site events, without severe or persistent cases; this supplies no universal recovery timetable. Record whether your symptom improves, worsens or recurs. [2]

›Is Leqvio better tolerated than statins?

These studies do not establish that. ORION-10 and ORION-11 compared inclisiran with placebo, not statins in a head-to-head tolerability trial. Comparing percentages from unrelated studies cannot tell you which treatment you personally would tolerate better. Discuss your specific previous reactions with your treating team. [2]

›Does Leqvio cause muscle pain?

The adult label table does not quantify muscle-pain risk. Its threshold captures common reactions reported more often than with placebo. Record new muscle symptoms for evaluation; attributing them to expectation or the injection requires more evidence. [1]

›Why do online reviews for Leqvio seem more negative than the trial data suggests?

Reviews and trials collect experiences differently. Reviewers select themselves, and negative experiences may motivate posting; we have not measured that pattern for Leqvio. Reviews may also combine symptoms with appointment, coverage or billing complaints. Trials use defined populations, follow-up and event collection, so their rates answer a different question.

›What symptoms after a Leqvio injection warrant a call to my doctor?

Get emergency help for difficulty breathing or swallowing, or facial or throat swelling. MedlinePlus advises immediate contact or emergency treatment for itching, rash or hives. Contact your treating team about worsening local symptoms or persistent symptoms affecting activity. [5]

References

Sources checked October 14, 2026.

1. LEQVIO prescribing information: adult adverse reactions and postmarketing hypersensitivity reports — DailyMed
2. Ray et al., 2020: Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol — ORION-10 and ORION-11
3. Ray et al., 2023: Four-year inclisiran follow-up in the open-label ORION-3 extension
4. Wright et al., 2024: Long-term efficacy and safety in the open-label ORION-8 extension
5. Inclisiran injection: symptoms requiring immediate medical attention — MedlinePlus